MICHELLE CHAMBRONE: Open Payments
NPI 1295728939 · NEW HARTFORD, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,280 in 112 payments from 21 companies in 2025. Trend: 2023 $2,418 · 2024 $2,476 · 2025 $2,280
Food & beverage: $2,280
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 33 | $612 |
| Novo Nordisk Inc | 5 | $207 |
| AstraZeneca Pharmaceuticals LP | 9 | $193 |
| Amgen Inc. | 14 | $186 |
| PFIZER INC. | 10 | $184 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $125 |
| Lilly USA, LLC | 7 | $121 |
| Astellas Pharma US Inc | 5 | $111 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $98 |
| Abbott Laboratories | 4 | $80 |
Products named: VRAYLAR, QULIPTA, Ozempic, OTEZLA, CAPLYTA, Veozah, UBRELVY, MOUNJARO.
Industry payments across NY — which companies pay providers there.
